Status:
RECRUITING
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Conditions:
Acute Kidney Injury
Renal Transplantation
Eligibility:
All Genders
18+ years
Brief Summary
Donor-derived cell-free DNA (dd-cfDNA) has been proposed as a potential diagnostic tool to monitor the rejection status of the kidney transplant. It has been suggested that dd-cfDNA is increasing in t...
Detailed Description
At the diagnostic level, routine monitoring of graft functionality after kidney transplantation relies on the use of non-specific markers, such as serum creatinine (allowing estimation of glomerular f...
Eligibility Criteria
Inclusion
- Age ≥ 18 years old
- With end-stage renal failure
- Summoned for a kidney transplant at Pitié Salpêtrière Hospital
- Having been informed of the study and not objecting to the study having given free and informed written consent for the genetic analysis
- Benefiting from a social security scheme (excluding AME)
Exclusion
- Under legal protective measures (curatorship or guardianship, under judicial safeguard).
Key Trial Info
Start Date :
September 2 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
July 9 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06026592
Start Date
September 2 2024
End Date
July 9 2026
Last Update
September 24 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pitié-Salpétriêre Hospital
Paris, Île-de-France Region, France, 75013